Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Return on Invested Capital (2023 - 2025)

Spero Therapeutics (SPRO) has disclosed Return on Invested Capital for 2 consecutive years, with 1.66% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Invested Capital fell 166.0% year-over-year to 1.66%, compared with a TTM value of 1.66% through Sep 2025, down 166.0%, and an annual FY2023 reading of 0.21%, changed N/A over the prior year.
  • Return on Invested Capital was 1.66% for Q3 2025 at Spero Therapeutics, down from 0.0% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.0% in Q3 2024 and bottomed at 1.66% in Q3 2025.